Liên Minh Châu Âu - Tiếng Malt - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin hydrochloride - diabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Liên Minh Châu Âu - Tiếng Malt - EMA (European Medicines Agency)

novartis europharm limited - valsartan, amlodipine (as amlodipine besilate) - pressjoni għolja - aġenti li jaġixxu fuq is-sistema renin-angiotensin - trattament ta 'ipertensjoni essenzjali. exforge huwa indikat f'pazjenti li l-pressjoni tad-demm mhijiex ikkontrollata adegwatament bl-amlodipina jew valsartan monoterapija.

Liên Minh Châu Âu - Tiếng Malt - EMA (European Medicines Agency)

amicus therapeutics europe limited - migalastat hydrochloride - marda ta 'fabry - migalastat - galafold huwa indikat għall-kura fit-tul ta ' l-adulti u l-adolexxenti ta ' età ta ' 16-il sena u aktar antiki mal-djanjosi konfermata tal-marda ta ' l-fabry (α-galactosidase a defiċjenza) u li jkollu l-mutazzjoni amenabbli.

Liên Minh Châu Âu - Tiếng Malt - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, tip 2 - drogi użati fid-dijabete - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Liên Minh Châu Âu - Tiếng Malt - EMA (European Medicines Agency)

novartis europharm limited - indacaterol maleate - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - hirobriz breezhaler huwa indikat għat-trattament tal-bronkodilatur tal-manteniment ta 'l-imblukkar tal-fluss ta' l-arja f'pazjenti adulti b'mard pulmonari ostruttiv kroniku.

Liên Minh Châu Âu - Tiếng Malt - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin hydrochloride - diabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 u 5. 1 għad-data disponibbli dwar kombinazzjonijiet differenti).

Liên Minh Châu Âu - Tiếng Malt - EMA (European Medicines Agency)

novartis europharm limited - canakinumab - cryopyrin-associated periodic syndromes; arthritis, juvenile rheumatoid; arthritis, gouty - impedituri ta ' interlukin, - perjodiċi deni syndromesilaris huwa indikat għall-kura ta 'dawn li ġejjin min-naħa perjodiċi deni sindromi fl-adulti, l-adoloxxenti u t-tfal ta' bejn 2-il sena u akbar:perjodiċi assoċjati mal-cryopyrin syndromesilaris huwa indikat għall-kura ta assoċjati mal-cryopyrin sindromi perjodiċi (limiti) inkluż:muckle-bjar sindromu (mws),neonatal-onset multisystem marda infjammatorja (nomid) / kronika infantili newroloġiku, vaskulite, artikulari sindromu (cinca),forom severi ta familjali kiesaħ min-naħa sindromu (fcas) / familjali kiesaħ urtikarja (li jidhru permezz) li ppreżentaw b'sinjali u s-sintomi lil hinn mill-kesħa indotta urtikarjali raxx tal-ġilda. - riċettur tal-fattur tan-nekrożi minn tumur perjodiċi assoċjati sindromu (nases)ilaris huwa indikat għall-kura tal-fattur ta'nekrożi tumorali (tnf) tar-riċettur tal-perjodiċi assoċjati sindromu (nases). hyperimmunoglobulin d-sindromu (hids)/mevalonate kinase defiċjenza (mkd)ilaris huwa indikat għall-kura ta hyperimmunoglobulin d-sindromu (hids)/mevalonate kinase defiċjenza (mkd). familjali-mediterran deni (fmf)ilaris huwa indikat għall-kura ta familjali-mediterran deni (fmf). ilaris għandu jingħata flimkien ma ' colchicine, jekk xieraq. ilaris huwa indikat ukoll għal trattament ta': xorta - diseaseilaris huwa indikat għall-kura ta attiva xorta tal-marda inkluż fl-adulti bidu xorta tal-marda (aosd) u sistemika, artrite idjopatika ġuvenili (sjia) f'pazjenti fl-etajiet ta'2-il sena u akbar fl-età li ma kellhomx rispons xieraq għat-terapija preċedenti ma ' mediċini mhux sterojdi kontra l-infjammazzjoni (nsaids), u kortikosterojdi sistemiċi. ilaris jista 'jingħata bħala monoterapija jew flimkien ma' methotrexate. - gotta arthritisilaris huwa indikat għall-kura sintomatika ta 'pazjenti adulti b'frekwenti artrite tal-gotta attakki (mill-inqas 3 attakki fl-aħħar 12-il xahar) f'min non-steroidal anti-inflammatory drugs (nsaids) u colchicine huma kontra-indikat, huma ma jkunux jifilħu għaliha, jew ma jipprovdu rispons adegwat, u li l-korsijiet ripetuti ta' kortikosterojdi ma jkunux xierqa.

Liên Minh Châu Âu - Tiếng Malt - EMA (European Medicines Agency)

novartis europharm ltd. - l-amlodipina, valsartan, hydrochlorothiazide - pressjoni għolja - antagonisti ta 'angiotensin ii, sempliċi, antagonisti ta' angiotensin ii, kombinazzjonijiet - trattament ta ' l-ipertensjoni essenzjali bħala terapija ta ' sostituzzjoni fil-pazjenti adulti l-pressjoni tad-demm tagħhom huwa kontrollat adegwatament dwar il-kombinazzjoni ta ' amlodipine, valsartan u idrochlorothiazide (hct), meħuda bħala tliet formulazzjonijiet ta ' wieħed il-komponent jew bħala a doppju-komponent u formulazzjoni wieħed-komponent.

Liên Minh Châu Âu - Tiếng Malt - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - umeclidinium bromide - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - indikat bħala trattament ta 'manteniment tal-bronkodilatur biex itaffi s-sintomi f'pazjenti adulti b'mard pulmonari ostruttiv kroniku (copd).

Liên Minh Châu Âu - Tiếng Malt - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - eptifibatide - angina, unstable; myocardial infarction - aġenti antitrombotiċi - integrilin huwa maħsub għall-użu ma 'acetylsalicylic acid u heparin mhux frazzjonat. integrilin huwa indikat għall-prevenzjoni ta 'infart mijokardijaku bikri f'pazjenti li jippreżentaw b'anġina instabbli jew mhux-mewġa-q infart mijokardijaku bl-aħħar episodju ta' uġigħ fis-sider li jseħħu fi żmien 24 siegħa u mal-bidliet fl-ecg u / jew enzimi kardijaċi elevati. il-pazjenti l-aktar probabbli li jibbenefikaw mill-integrilin-trattament huma dawk f'riskju għoli li jiżviluppaw infart mijokardijaku fi żmien l-ewwel 3-4 ijiem wara l-bidu ta 'anġina' sintomi, inkluż pereżempju dawk li huma probabbli li jgħaddu minn kmieni koronarju perkutanju transluminali l-anġoplastika (ptca).